Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

  title={Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents},
  author={G. Griebel and J. Stemmelin and B. Scatton},
  journal={Biological Psychiatry},
  • G. Griebel, J. Stemmelin, B. Scatton
  • Published 2005
  • Psychology, Medicine
  • Biological Psychiatry
  • BACKGROUND The endocannabinoid system has been implicated in the modulation of emotional processes. METHODS These experiments aimed to investigate the effects of the cannabinoid CB1 receptor antagonist rimonabant (SR141716) in animal models measuring aspects of emotional reactivity and depression. RESULTS Rimonabant had weak anxiolytic-like activity in the elevated plus-maze and failed to affect flight and risk assessment activities in the mouse defense test battery (MDTB). It produced… CONTINUE READING
    230 Citations
    Cannabinoid CB1 receptor in the modulation of stress coping behavior in mice: The role of serotonin and different forebrain neuronal subpopulations
    • 54
    • Highly Influenced
    • PDF
    Antiaversive Effects of Cannabinoids: Is the Periaqueductal Gray Involved?
    • 56
    • PDF
    Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice
    • 86
    • Highly Influenced
    Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats
    • 119


    Involvement of CB1 cannabinoid receptors in emotional behaviour
    • 437
    • PDF
    Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters
    • 173
    • PDF
    Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety‐like responses in the rat
    • 305
    ‘One‐trial sensitization’ to the anxiolytic‐like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus‐maze
    • 91
    The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions
    • 262
    Behavioral effects of cannabinoid agents in animals.
    • 300